Clearside Biomedical Inc. (CLSD)
Clearside Biomedical Statistics
Share Statistics
Clearside Biomedical has 75.84M shares outstanding. The number of shares has increased by 1.49% in one year.
| Shares Outstanding | 75.84M |
| Shares Change (YoY) | 1.49% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 12.63% |
| Shares Floating | 63.89M |
| Failed to Deliver (FTD) Shares | 2.89K |
| FTD / Avg. Volume | 1.41% |
Short Selling Information
The latest short interest is 1.76M, so 2.32% of the outstanding shares have been sold short.
| Short Interest | 1.76M |
| Short % of Shares Out | 2.32% |
| Short % of Float | 2.74% |
| Short Ratio (days to cover) | 1.21 |
Valuation Ratios
The PE ratio is undefined and the forward PE ratio is -2.1. Clearside Biomedical's PEG ratio is undefined.
| PE Ratio | undefined |
| Forward PE | -2.1 |
| PS Ratio | 0 |
| Forward PS | 0.6 |
| PB Ratio | -1.8 |
| P/FCF Ratio | undefined |
| PEG Ratio | undefined |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Clearside Biomedical Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.44, with a Debt / Equity ratio of undefined.
| Current Ratio | 4.44 |
| Quick Ratio | 4.44 |
| Debt / Equity | undefined |
| Total Debt / Capitalization | -1.84 |
| Cash Flow / Debt | -35.13 |
| Interest Coverage | undefined |
Financial Efficiency
Return on equity (ROE) is 0.88% and return on capital (ROIC) is 75.7%.
| Return on Equity (ROE) | 0.88% |
| Return on Assets (ROA) | -1.37% |
| Return on Capital (ROIC) | 75.7% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1,145,066.67 |
| Employee Count | 30 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -41.77% in the last 52 weeks. The beta is 2.1, so Clearside Biomedical's price volatility has been higher than the market average.
| Beta | 2.1 |
| 52-Week Price Change | -41.77% |
| 50-Day Moving Average | 0.96 |
| 200-Day Moving Average | 1.07 |
| Relative Strength Index (RSI) | 45.46 |
| Average Volume (20 Days) | 204.06K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -28.88M |
| Net Income | -34.35M |
| EBITDA | -28.88M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.47 |
Balance Sheet
The company has 20.02M in cash and 703K in debt, giving a net cash position of 19.32M.
| Cash & Cash Equivalents | 20.02M |
| Total Debt | 703K |
| Net Cash | 19.32M |
| Retained Earnings | -355.27M |
| Total Assets | 29.16M |
| Working Capital | 19.52M |
Cash Flow
In the last 12 months, operating cash flow was -24.7M and capital expenditures 0, giving a free cash flow of -24.7M.
| Operating Cash Flow | -24.7M |
| Capital Expenditures | 0 |
| Free Cash Flow | -24.7M |
| FCF Per Share | -0.33 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CLSD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -51.09% |
| FCF Yield | -35.54% |
Analyst Forecast
The average price target for CLSD is $5, which is 443.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 443.5% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -17.44 |
| Piotroski F-Score | 3 |